JMP Securities analyst Liisa Bayko noted that Sarepta’s gene therapy showed robust improvement in functional endpoints in the latest data from the program, which she sees “reinforcing the leapfrog this platform can offer” in Duchenne muscular dystrophy. The safety also still looks acceptable, added Bayko, who reiterates her Outperform rating and $270 price target on Sarepta shares.
No comments:
Post a Comment
Note: Only a member of this blog may post a comment.